These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38582712)

  • 1. Association between remnant cholesterol and metabolic dysfunction-associated steatotic liver disease in the elderly.
    Lan Y; Guo Z; Dai J; Chen K; Chen Y
    Dig Liver Dis; 2024 Sep; 56(9):1557-1564. PubMed ID: 38582712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remnant cholesterol is associated with the progression and regression of metabolic dysfunction-associated steatotic liver disease in Chinese adults.
    Guo W; Lu J; Li X; Zhao X; Xu N; Diao Q; Jia J; Zhang Q
    J Clin Lipidol; 2024; 18(4):e509-e517. PubMed ID: 38960813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased visceral fat area to skeletal muscle mass ratio is positively associated with the risk of metabolic dysfunction-associated steatotic liver disease in a Chinese population.
    Liu C; Li N; Sheng D; Shao Y; Qiu L; Shen C; Liu Z
    Lipids Health Dis; 2024 Apr; 23(1):104. PubMed ID: 38616253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between neutrophil-to-high-density lipoprotein cholesterol ratio and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in the US population: a nationally representative cross-sectional study using NHANES data from 2017 to 2020.
    Lu Y; Xu X; Wu J; Ji L; Huang H; Chen M
    BMC Gastroenterol; 2024 Sep; 24(1):300. PubMed ID: 39237899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of remnant cholesterol with chronic kidney disease in middle-aged and elderly Chinese: a population-based study.
    Yan P; Xu Y; Miao Y; Bai X; Wu Y; Tang Q; Zhang Z; Yang J; Wan Q
    Acta Diabetol; 2021 Dec; 58(12):1615-1625. PubMed ID: 34181081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased serum carboxylesterase-1 levels are associated with metabolic dysfunction associated steatotic liver disease and metabolic syndrome in children with obesity.
    Wang H; Wu S; Weng Y; Yang X; Hou L; Liang Y; Wu W; Ying Y; Ye F; Luo X
    Ital J Pediatr; 2024 Sep; 50(1):162. PubMed ID: 39227971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and risk factors of metabolic dysfunction-associated steatotic liver disease in south Central Uganda: A cross-sectional survey.
    Enriquez R; Homsi M; Ssekubugu R; Nabukalu D; Zeebari Z; Marrone G; Gigante B; Chang LW; Reynolds SJ; Nalugoda F; Ekström AM; Hagström H; Nordenstedt H
    Aliment Pharmacol Ther; 2024 May; 59(9):1111-1121. PubMed ID: 38459720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of muscle mass, grip strength and fat-to-muscle ratio and metabolic dysfunction-associated steatotic liver disease in a middle-to-elderly aged population.
    Liu S; He Y; Yu G; Song C; Wang D; Liu L; Liang H; Wan H; Shen J
    Ann Med; 2024 Dec; 56(1):2390169. PubMed ID: 39129458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Associations between Healthy Eating Patterns and Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Case-Control Study.
    Huang X; Gan D; Fan Y; Fu Q; He C; Liu W; Li F; Ma L; Wang M; Zhang W
    Nutrients; 2024 Jun; 16(12):. PubMed ID: 38931312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.
    Sato A; Oomori Y; Nakano R; Matsuura T
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202611
    [No Abstract]   [Full Text] [Related]  

  • 11. Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.
    Wu T; Ye J; Mo S; Ye M; Li X; Li Q; Wang W; Zheng Q; Luo K; Zhang Y; Tu S; Che D; Gong R; Chen X; Miu R; Shao C; Sun Y; Zhong B
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1636-1647. PubMed ID: 38695344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes.
    Aernouts C; Beldé SPW; Lambrechts J; Mertens J; Ledeganck KJ; Francque SM; De Block CEM
    Diabetes Obes Metab; 2024 Sep; 26(9):3781-3790. PubMed ID: 38924290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis/cirrhosis among adolescents/young adults.
    Perumpail BJ; Manikat R; Wijarnpreecha K; Cholankeril G; Ahmed A; Kim D
    J Pediatr Gastroenterol Nutr; 2024 Jul; 79(1):110-118. PubMed ID: 38623942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in Oxidative Balance Score and Prevalence of Metabolic Dysfunction-Associated Steatotic Liver Disease in the United States: National Health and Nutrition Examination Survey 2001 to 2018.
    Tan Z; Wu Y; Meng Y; Liu C; Deng B; Zhen J; Dong W
    Nutrients; 2023 Nov; 15(23):. PubMed ID: 38068789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.
    Li X; He J; Sun Q
    Clin Nutr; 2024 Sep; 43(9):2005-2016. PubMed ID: 39053329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycaemic control metrics and metabolic dysfunction-associated steatotic liver disease in children and adolescents with type 1 diabetes.
    Maffeis C; Piona C; Morandi A; Marigliano M; Morotti E; Mancioppi V; Caiazza E; Zusi C; Emiliani F; Mantovani A; Colecchia A; Targher G
    Diabetes Obes Metab; 2024 Dec; 26(12):5896-5905. PubMed ID: 39344839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes.
    Castellano-Castillo D; Núñez-Sánchez MÁ; Balaguer-Román A; Martínez-Sánchez MA; Fernández-Ruiz VE; Ferrer-Gómez M; Martínez CM; Frutos MD; Queipo-Ortuño MI; Cardona F; Ramos-Molina B
    Surg Obes Relat Dis; 2024 Jul; 20(7):652-659. PubMed ID: 38490825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triglyceride to HDL Cholesterol Ratio for the Identification of MASLD in Obesity: A Liver Biopsy-Based Case-Control Study.
    Martínez-Montoro JI; Martínez-Sánchez MA; Balaguer-Román A; Fernández-Ruiz VE; Hernández-Barceló JE; Ferrer-Gómez M; Frutos MD; Núñez-Sánchez MÁ; Fernández-García JC; Ramos-Molina B
    Nutrients; 2024 Apr; 16(9):. PubMed ID: 38732557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, proportions of elevated liver enzyme levels, and long-term cardiometabolic mortality of patients with metabolic dysfunction-associated steatotic liver disease.
    Chen YT; Chen TI; Yin SC; Huang CW; Huang JF; Lu SN; Yeh ML; Huang CF; Dai CY; Chen YW; Chuang WL; Yu ML; Lee MH
    J Gastroenterol Hepatol; 2024 Sep; 39(9):1939-1949. PubMed ID: 38725327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anxiety and depression in metabolic-associated steatotic liver disease: relation with socio-demographic features and liver disease severity.
    Brodosi L; Stecchi M; Musio A; Bazzocchi M; Risi E; Marchignoli F; Marchesini G; Petroni ML
    Acta Diabetol; 2024 Aug; 61(8):1041-1051. PubMed ID: 38684539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.